PER-091-06已完成未知
An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy
OVARTIS BIOSCIENSES PERU S.A.,0 个研究点目标入组 0 人开始时间: 2007年1月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) Outpatients 18 years of age and older.
- •2) Male or female patients are eligible.
- •3) Patients with a diagnosis of hypertension.
- •4) Patients who are eligible and able to participate in the study, and who have given their consent after the purpose and nature of the research has been clearly explained to them.
排除标准
- •1. Women who are pregnant or breastfeeding.
- •2. Women with reproductive potential, UNLESS they meet the definition of a postmenopausal woman OR who are using one or more of the acceptable methods of contraception.
- •3. Severe hypertension.
- •4. History or evidence of a secondary form of hypertension.
- •5. Known Keith-Wagener hypertensive retinopathy Grade III or IV.
- •6. Current or previous diagnosis of heart failure.
- •7. History of hypertensive encephalopathy or cerebrovascular accident, transient ischemic attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention (PCI).
- •8. Serum potassium <3.5 mEq / L or ≥ 5.3 mEq / L, serum sodium less than the normal limit or dehydration.
- •9. Patients with type 1 or type 2 diabetes mellitus that are not well controlled.
- •10. Current pectoris angina that requires pharmacological therapy.
- •11. Second or third degree heart block without a pacemaker.
- •12. Atrial fibrillation or atrial flutter in Visit 1, or any symptomatic or life-threatening arrhythmia during the 12 months prior to Visit 1.
- •13. Clinically significant valvular heart disease.
- •14. Any medication, surgical or medical condition, that could significantly alter the absorption, distribution, metabolism, or excretion of investigational medications.
- •15. History of hypersensitivity to any of the medications or drugs that belong to the similar therapeutic class.
- •16. History of angioedema due to the use of a lECA or ARB.
- •17. History of malignancy in the last 5 years.
- •18. History of gouty arthritis.
- •19. History or evidence of drug or alcohol abuse in the last 12 months.
- •20. Any surgical or medical condition that could place the patient at greater risk due to his participation in the study, or that probably prevents the patient from meeting the requirements of the study or the completion of the study.
- •21. Patients who have been previously recruited during the active period of drug treatment from a clinical trial that has had the aliskiren / HCTZ combination treatment.
- •22. Use of other investigational drugs at the time of recruitment, or within 30 days or 5 half-lives of recruitment, whichever is longer.
- •23. History of noncompliance with medical regimens or lack of will to comply with the study protocol.
- •24. Any condition that could confuse the evaluation and interpretation of efficacy and / or safety data.
- •25. Persons directly involved in the execution of this protocol.
研究者
相似试验
招募中
1 期
A Study to Evaluate Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED)Thyroid Eye DiseaseCTIS2022-502812-35-00Sling Therapeutics Inc.75
进行中（未招募）
1 期
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisPlaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858EUCTR2015-002423-26-EEovartis Pharma Services AG196
撤回
4 期
A randomized, multicenter Study to evaluate the Effect of secukinumab 300 mg s.c. administered during 52 Weeks to patients suffering from new-onset moderate to severe plaque Psoriasis as early Intervention compared to standard treatment with narrow band UVB (STEPin study)plaque psoriasispsoriasis vulgaris10014982NL-OMON43019TFS Trial Form Support BV20
进行中（未招募）
1 期
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisPlaque psoriasisEUCTR2015-002423-26-PLovartis Pharma Services AG196
进行中（未招募）
1 期
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000018190Plaque psoriasisEUCTR2015-002423-26-HUovartis Pharma Services AG196